{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T16:12:26Z","timestamp":1760458346947,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11625-8","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:51:34Z","timestamp":1760457094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Azvudine with severe outcomes among hospitalized patients with COVID-19 during an omicron-dominance period in Wuhan, China: a single-center, retrospective, matched cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Zihao","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanji","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyu","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"19","key":"11625_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813\u201326.","journal-title":"N Engl J Med"},{"issue":"15","key":"11625_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397\u2013408.","journal-title":"N Engl J Med"},{"issue":"6","key":"11625_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509\u201320.","journal-title":"N Engl J Med"},{"issue":"10373","key":"11625_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2023","unstructured":"Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281\u201393.","journal-title":"Lancet"},{"issue":"1","key":"11625_CR5","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1093\/cid\/ciab1035","volume":"75","author":"BT Garibaldi","year":"2022","unstructured":"Garibaldi BT, Wang K, Robinson ML, Betz J, Caleb Alexander G, Andersen KM, et al. Real-world effectiveness of Remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): A retrospective, multicenter comparative effectiveness study. Clin Infect Dis. 2022;75(1):e516\u201324.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"11625_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","volume":"387","author":"R Arbel","year":"2022","unstructured":"Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N Engl J Med. 2022;387(9):790\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"11625_CR7","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-Risk patients. Clin Infect Dis. 2023;76(3):e342\u20139.","journal-title":"Clin Infect Dis"},{"issue":"10359","key":"11625_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"CKH Wong","year":"2022","unstructured":"Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus Ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the Omicron wave in Hong kong: an observational study. Lancet. 2022;400(10359):1213\u201322.","journal-title":"Lancet"},{"issue":"12","key":"11625_CR9","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","volume":"22","author":"CKH Wong","year":"2022","unstructured":"Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong kong\u2019s Omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681\u201393.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"11625_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00351-z","volume":"5","author":"B Yu","year":"2020","unstructured":"Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduct Target Ther. 2020;5(1):236.","journal-title":"Signal Transduct Target Ther"},{"key":"11625_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00204-20","author":"N Xu","year":"2020","unstructured":"Xu N, Yang J, Zheng B, Zhang Y, Cao Y, Huan C, et al. The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses. J Virol. 2020. https:\/\/doi.org\/10.1128\/JVI.00204-20.","journal-title":"J Virol"},{"issue":"19","key":"11625_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202001435","volume":"7","author":"Z Ren","year":"2020","unstructured":"Ren Z, Luo H, Yu Z, Song J, Liang L, Wang L, et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv Sci. 2020;7(19):e2001435.","journal-title":"Adv Sci"},{"issue":"1","key":"11625_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00835-6","volume":"6","author":"J-L Zhang","year":"2021","unstructured":"Zhang J-L, Li Y-H, Wang L-L, Liu H-Q, Lu S-Y, Liu Y, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):414.","journal-title":"Signal Transduct Target Ther"},{"key":"11625_CR14","doi-asserted-by":"publisher","unstructured":"Shen M, Xiao C, Sun Y, Li D, Wu P, Jin L et al. Real-world effectiveness of azvudine in hospitalized patients with COVID-19: a retrospective cohort study. BioRxiv. 2023.Available from: https:\/\/doi.org\/10.1101\/2023.01.23.23284899.","DOI":"10.1101\/2023.01.23.23284899"},{"issue":"101981","key":"11625_CR15","doi-asserted-by":"publisher","first-page":"101981","DOI":"10.1016\/j.eclinm.2023.101981","volume":"59","author":"Y Sun","year":"2023","unstructured":"Sun Y, Jin L, Dian Y, Shen M, Zeng F, Chen X, et al. Oral azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine. 2023;59(101981):101981.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"11625_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28947","volume":"95","author":"H Yang","year":"2023","unstructured":"Yang H, Wang Z, Jiang C, Zhang Y, Zhang Y, Xu M, et al. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: results of a real-world study. J Med Virol. 2023;95(7):e28947.","journal-title":"J Med Virol"},{"issue":"7","key":"11625_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28940","volume":"95","author":"Y Gao","year":"2023","unstructured":"Gao Y, Luo Z, Hu Z, Ma Y. Real-world effectiveness of azvudine: elixir or equivocal answer? J Med Virol. 2023;95(7):e28940.","journal-title":"J Med Virol"},{"key":"11625_CR18","unstructured":"CDC. COVID-19 treatments and medications. Centers for Disease Control and Prevention. 2023 [cited 2023 Aug 7]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/your-health\/treatments-for-severe-illness.html"},{"issue":"7965","key":"11625_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/d41586-023-01872-7","volume":"618","author":"Y Ye","year":"2023","unstructured":"Ye Y. China\u2019s rolling COVID waves could hit every six months - infecting millions. Nature. 2023;618(7965):442\u20133.","journal-title":"Nature"},{"key":"11625_CR20","unstructured":"Transcript of the press conference of the Joint Prevention and Control Mechanism of the State Council on December 7. 2022. Gov.cn. [cited 2023 Aug 7]. Available from: http:\/\/www.nhc.gov.cn\/xcs\/s3574\/202212\/0001cc3efcce46e8aad5c4f40c66da55.shtml"},{"key":"11625_CR21","unstructured":"Notice on Printing and Distributing the Diagnosis and Treatment Plan for Novel Coronavirus Infection. (Trial Version 10). Gov.cn. [cited 2023 Aug 7]. Available from: https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023-01\/06\/content_5735343.htm"},{"issue":"8","key":"11625_CR22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/aje\/kwab028","volume":"190","author":"C Renoux","year":"2021","unstructured":"Renoux C, Azoulay L, Suissa S. Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: designing real-world evidence studies. Am J Epidemiol. 2021;190(8):1452\u20136.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"11625_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/bimj.200810488","volume":"51","author":"PC Austin","year":"2009","unstructured":"Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and monte carlo simulations. Biom J. 2009;51(1):171\u201384.","journal-title":"Biom J"},{"issue":"5","key":"11625_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101049","volume":"4","author":"JN Faraone","year":"2023","unstructured":"Faraone JN, Qu P, Evans JP, Zheng Y-M, Carlin C, Anghelina M, et al. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants. Cell Rep Med. 2023;4(5):101049.","journal-title":"Cell Rep Med"},{"issue":"100849","key":"11625_CR25","first-page":"100849","volume":"37","author":"R Pung","year":"2023","unstructured":"Pung R, Kong XP, Cui L, Chae S-R, Chen MI-C, Lee VJ, et al. Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore. Lancet Reg Health West Pac. 2023;37(100849):100849.","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"11625_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.15585\/mmwr.mm7205e1","volume":"72","author":"R Link-Gelles","year":"2023","unstructured":"Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB\/XBB.1.5-related sublineages among immunocompetent adults - Increasing community access to testing program, united states, december 2022-january 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):119\u201324.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"11625_CR27","doi-asserted-by":"publisher","first-page":"e235755","DOI":"10.1001\/jamanetworkopen.2023.5755","volume":"6","author":"K Wang","year":"2023","unstructured":"Wang K, Guo Z, Zeng T, Sun S, Lu Y, Wang J, et al. Transmission characteristics and inactivated vaccine effectiveness against transmission of SARS-CoV-2 Omicron BA.5 variants in Urumqi, China. JAMA Netw Open. 2023;6(3):e235755.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"11625_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/joim.13063","volume":"288","author":"J Wu","year":"2020","unstructured":"Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020;288(1):128\u201338.","journal-title":"J Intern Med"},{"key":"11625_CR29","unstructured":"Therapies. COVID-19 Treatment Guidelines. [cited 2023 Aug 8]. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/"},{"key":"11625_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28756","author":"G Deng","year":"2023","unstructured":"Deng G, Li D, Sun Y, Jin L, Zhou Q, Xiao C, et al. Real-world effectiveness of azvudine versus nirmatrelvir\u2013ritonavir in hospitalized patients with COVID\u201019: a retrospective cohort study. J Med Virol. 2023. https:\/\/doi.org\/10.1002\/jmv.28756.","journal-title":"J Med Virol"},{"issue":"2","key":"11625_CR31","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.jinf.2023.05.012","volume":"87","author":"Y Dian","year":"2023","unstructured":"Dian Y, Meng Y, Sun Y, Deng G, Zeng F. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Infect. 2023;87(2):e24-7.","journal-title":"J Infect"},{"issue":"6","key":"11625_CR32","volume":"3","author":"B Yu","year":"2022","unstructured":"Yu B, Chang J. The first Chinese oral anti-COVID-19 drug azvudine launched. Innov (Camb). 2022;3(6):100321.","journal-title":"Innov (Camb)"},{"issue":"6","key":"11625_CR33","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1016\/j.jinf.2023.03.023","volume":"86","author":"Y Gao","year":"2023","unstructured":"Gao Y, Luo Z, Ren S, Duan Z, Han Y, Liu H, et al. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19. J Infect. 2023;86(6):e158\u201360.","journal-title":"J Infect"},{"issue":"1","key":"11625_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00277-x","volume":"3","author":"LL Dietz","year":"2023","unstructured":"Dietz LL, Juhl AK, S\u00f8gaard OS, Reekie J, Nielsen H, Johansen IS, et al. Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity. Commun Med. 2023;3(1):58.","journal-title":"Commun Med"},{"issue":"2","key":"11625_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186\u201393.","journal-title":"Nat Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11625-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11625-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11625-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:51:35Z","timestamp":1760457095000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11625-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11625"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11625-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University (No.: 2023013\u00a0K). The need for obtaining informed consent to participate was waived by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University. This study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1325"}}